临床伴随药物对免疫检查点抑制剂治疗尿路上皮癌的影响研究进展

Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)已被批准用于尿路上皮癌的治疗,然而在治疗过程中部分患者因并发症使用抗生素、质子泵抑制剂、皮质类固醇、β⁃受体阻滞剂、二甲双胍和他汀类等伴随药物,可能通过不同途径影响ICIs的临床疗效,使患者产生耐药性,难以从临床获益。本文就上述临床伴随药物对ICIs治疗尿路上皮癌的影响作一综述,以期为临床开展ICIs个体化治疗提供参考。

Immune checkpoint inhibitors(ICIs)have been approved for the treatment of urothelial carci⁃noma(UC).However,the use of antibiotics,proton pump inhibitors,corticosteroids,beta⁃blockers,metformin,and statin concomitant medications in some patients due to complications during the treatment process may affect the clinical efficacy of ICIs through different pathway,making it difficult for patients to derive clinical benefit or making it more likely to develop drug resistance.In this paper,we present a review of the effects of the above concomitant drugs on ICIs in the treatment of patients with advanced UC,with a view to provide reference for the application of individualized treatment strategies of ICIs in patients with advanced UC.